SciELO - Scientific Electronic Library Online

 
vol.32 número1Diagnosis of monoclonal gammopathy of renal significanceC3 glomerulonephritis disguised as Postinfectious GN índice de autoresíndice de assuntosPesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Não possue artigos similaresSimilares em SciELO

Compartilhar


Portuguese Journal of Nephrology & Hypertension

versão impressa ISSN 0872-0169

Resumo

DI MARCO, Giovana S  e  BRAND, Marcus. Off-target effects and adverse outcomes of fibroblast growth factor 23 in chronic kidney disease. Port J Nephrol Hypert [online]. 2018, vol.32, n.1, pp.57-63. ISSN 0872-0169.

Chronic kidney disease (CKD) patients have a high risk of death, especially cardiovascular death. High fibroblast growth factor 23 (FGF23) levels are independently associated with higher risk of death and cardiovascular events in these patients, as well as with a greater risk of severe inflammation. Chronic inflammation contributes to the progression of renal disease, the pathogenesis of cardiovascular disease, and mortality. Moreover, clinically, the CKD-associated defect in the immune system also has a relevant impact on morbidity and mortality. Recent findings showing that excess FGF23 may affect non-traditional, off-target organs independently of αKlotho give support to the potential clinical relevance of the adverse effects of FGF23 in CKD, and even in non-CKD patients. In this review, we provide an update on FGF23 and briefly discuss its future in clinical practice

Palavras-chave : Chronic kidney disease (CKD); fibroblast growth factor 23 (FGF23); heart hypertrophy, inflammation.

        · texto em Inglês     · Inglês ( pdf )

 

Creative Commons License Todo o conteúdo deste periódico, exceto onde está identificado, está licenciado sob uma Licença Creative Commons